XNCR
Xencor IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$900.65M
P/E Ratio
—
EPS
$-1.24
Beta
0.99
52W High
$18.69
52W Low
$6.92
50-Day MA
$12.17
200-Day MA
$12.20
Dividend Yield
—
Profit Margin
-73.20%
Forward P/E
68.03
PEG Ratio
0.00
About Xencor Inc
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed to treat cancer patients and autoimmune diseases in the United States and internationally. The company is headquartered in Monrovia, California.
Fundamentals
| Revenue (TTM) | $125.58M |
| Gross Profit (TTM) | $-113.86M |
| EBITDA | $-166.99M |
| Operating Margin | -189.90% |
| Return on Equity | -14.10% |
| Return on Assets | -12.10% |
| Revenue/Share (TTM) | $1.69 |
| Book Value | $8.84 |
| Price-to-Book | 1.51 |
| Price-to-Sales (TTM) | 7.17 |
| EV/Revenue | 4.784 |
| EV/EBITDA | -17.27 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -46.50% |
| Shares Outstanding | $74.13M |
| Float | $53.85M |
| % Insiders | 1.26% |
| % Institutions | 119.34% |
Historical Volatility
HV 10-Day
60.86%
HV 20-Day
50.64%
HV 30-Day
53.52%
HV 60-Day
64.89%
HV Rank
15.5%
Volatility is currently expanding
Analyst Ratings
Consensus ($28.42 target)
3
Strong Buy9
Buy2
HoldData last updated: 4/29/2026